Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data | Zendy

Cornelius J. Clancy | Zendy; Brian A. Potoski | Zendy; Deanna J. Buehrle | Zendy; M. Hong Nguyen | Zendy

Open Access

Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data

Author(s) -

Cornelius J. Clancy,

Brian A. Potoski,

Deanna J. Buehrle,

M. Hong Nguyen

Publication year - 2019

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofz344

Subject(s) - polymyxin , medicine , colistin , antibiotics , carbapenem resistant enterobacteriaceae , ceftazidime/avibactam , polymyxin b , intensive care medicine , ceftazidime , enterobacteriaceae , microbiology and biotechnology , biology , escherichia coli , pseudomonas aeruginosa , biochemistry , genetics , gene , bacteria

New anti-CRE agents recently surpassed intravenous polymyxins as treatment for CRE infections, but use is less than expected from their positioning at US hospitals. Research on behavioral and economic factors that impact use of new antibiotics is needed, as are financial "pull" incentives that promote an economically viable marketplace.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research